Federal Court upholds patent validity and issues declarations of infringement against two generic apixaban tablets
PM(NOC) Regulations do not preclude defendants from amending the statement of defence
Pharma in Brief: The 2020 Year in Review
Divided success in PM(NOC) actions regarding glatiramer acetate
Prosecution history cannot be invoked against patent licensees
NOC issued after Federal Court overturns Minister’s decision on effective date of consent letter under the PM(NOC) Regulations
